| RRC ID |
75896
|
| Author |
Machino T, Okoshi Y, Miyake Y, Akatsuka Y, Chiba S.
|
| Title |
HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
|
| Journal |
Immunol Invest
|
| Abstract |
Risk of leukemia relapse after T cell-depleted hematopoietic stem cell transplantation is lower in the "HLA-C mismatched" recipient-donor combinations. This might be attributable to increased natural killing by allogeneic NK cells carrying a KIR that does not bind to HLA-C on target cells (HLA-C-uncoupled KIR). Considering a new strategy of allogeneic NK cell transfer with rituximab to treat B-cell lymphomas, however, it is unknown whether the HLA-C matching status also affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC). To address this issue, we investigated the levels of ADCC by purified NK cells carrying an HLA-C-uncoupled KIR, where the NK cell donors had either matched or mismatched HLA-C combination with target cells. Purified NK cells carrying an HLA-C-uncoupled KIR consistently showed enhanced ADCC against target cells when NK cell donors had an HLA-C-mismatch. When NK cell donors did not have an HLA-C mismatch, it was inconsistent whether HLA-C-uncoupled KIR caused ADCC enhancement. When the levels of ADCC by whole NK cells were compared, there were substantial differences among the donors regardless of the HLA-C matching status. Subjects with HLA-C mismatch may not have an advantage when cytoimmunotherapy using allogeneic NK cells is considered in combination with rituximab.
|
| Volume |
41(8)
|
| Pages |
831-46
|
| Published |
2012-1-1
|
| DOI |
10.3109/08820139.2012.691148
|
| PMID |
22676066
|
| MeSH |
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
Antibody-Dependent Cell Cytotoxicity / immunology*
Antigens, CD20 / immunology
Antineoplastic Agents / administration & dosage*
B-Lymphocytes / immunology
Cell Line, Tumor
Gene Knockdown Techniques
HLA-C Antigens / genetics
HLA-C Antigens / immunology*
Histocompatibility*
Humans
Immunotherapy, Adoptive*
Isoantigens / immunology
Killer Cells, Natural / immunology
Killer Cells, Natural / transplantation*
Lymphocyte Depletion
Lymphoma / drug therapy
Lymphoma / therapy*
RNA, Small Interfering / genetics
Receptor Cross-Talk
Receptors, KIR / metabolism
Rituximab
Transplantation, Homologous
|
| IF |
2.511
|
| Resource |
| Human and Animal Cells |
RAJI(RCB1647) |
